Press Releases

11.03.2016

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

11.02.2016

Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China

11.01.2016

Pfizer Reports Third-Quarter 2016 Results

11.01.2016

Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor

10.30.2016

European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

10.21.2016

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

10.19.2016

CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)

10.19.2016

DILIsym Services, Inc. Utilizes Flagship Technology to Evaluate Prospective NAFLD Treatments in Collaboration with Pfizer Inc.

10.19.2016

Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection

10.17.2016

Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)

10.15.2016

Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016

10.09.2016

First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal